Shevan Silva

Auckland, AUK 1142, New Zealand

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.

Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506.

Journal: ACS medicinal chemistry letters

Published: July 24, 2023

Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.

Interrogation of the Structure-Activity Relationship of a Lipophilic Nitroaromatic Prodrug Series Designed for Cancer Gene Therapy Applications.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 16, 2021

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.

Restoring Tumour Selectivity of the Bioreductive Prodrug PR-104 by Developing an Analogue Resistant to Aerobic Metabolism by Human Aldo-Keto Reductase 1C3.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 01, 2021

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.

Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 08, 2020

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.

Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.

Journal: Biochemical pharmacology

Published: May 25, 2016

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.

Journal: Journal of structural biology

Published: June 17, 2015

Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).

Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3).

Journal: Bioorganic & medicinal chemistry

Published: October 18, 2013

Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.

Synthesis and structure-activity relationships for 1-(4-(piperidin-1-ylsulfonyl)phenyl)pyrrolidin-2-ones as novel non-carboxylate inhibitors of the aldo-keto reductase enzyme AKR1C3.

Journal: European journal of medicinal chemistry

Published: October 16, 2012

3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.

3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3.

Journal: Journal of medicinal chemistry

Published: August 11, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026